/stocks — the workspaceLOADING
All NVOSEC filings, by type → · Earnings date & implied move · Search inside filings
NOVO NORDISK A S (NVO) is a pharmaceutical preparations company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind NVO’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has NVO been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
A plain-English read on NVO plus an auto-SWOT — built from NVO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate NVO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from NVO's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentNVO files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in NVO in the latest 13F round.
Total return including reinvested dividends, from NVO’s adjusted closing prices. Past return is not a forecast and not investment advice.
| Alan ArmstrongU.S. Senator | BUY | $15,001 - $50,000 | filed 2026-07-21 |
No open-market Form 4 buys or sells reported for NVO in the last ~6 months.